- Details
- Jens Bedke enthusiastically discusses the transformation in first-line treatment of RCC from monotherapy, which has been the standard of care on the treatment of RCC to now combination therapies. The first-line therapy with a combination of an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) improved outcomes in patients with clear-cell metastatic renal cell carcinoma (mRCC), as c...
|
- Details
- Thomas Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium with Charles Ryan. The checkpoint inhibitor pembrolizumab plus the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor axitinib significantly improved overall survival, progression-free survival, and objective response rates vs sunitinib as first-line therapy...
|
- Details
- Rana McKay, MD reviews the evolving landscape for the frontline treatment of metastatic RCC. Historically, patients were treated with first-line TKIs although the paradigm has been shifting over the past two years including, VEGF targeted therapy with immunotherapy and IO-IO combinations. Dr. McKay reviews the data from KEYNOTE 426 with pembrolizumab plus axitinib which demonstrated a survival ben...
|
- Details
- Sandy Srinivas, MD discusses the frontline data from the KEYNOTE 426 trial comparing pembrolizumab plus axitinib to sunitinib monotherapy in clear cell kidney cancer. 800 patients were randomized and the combination demonstrated benefit across all three outcomes measured including response rates, PFS and overall survival. Dr. Srinivas believes the tolerability for pembrolizumab plus axitinib is mo...
|
- Details
- Primo Lara and Monty Pal discuss this exciting time in the evolving paradigm for the treatment of kidney cancer. They focus their discussion on the groundbreaking data presented at ASCO GU on the KEYNOTE 426 trial which demonstrated that the combination of pembrolizumab plus axitinib was superior to the VEGF RTKI, sunitinib. Overall survival with the combination demonstrated a 46% reduction in the...
|
- Details
- Dena Battle, President KCCure joins Jaime Landman and Monty Pal for a discussion on development and establishing resources to assist in the fight against kidney cancer. KCCure, is a research organization that funds high-impact, high-risk kidney cancer research through a peer-review processthrough an expert team of kidney cancer specialists, patients, caregivers, and kidney cancer advocates. The gr...
|
- Details
- Dan George and Tian Zhang share their views on monitoring treatment toxicities that patients with renal cell carcinoma may experience. Emphasis is placed on counseling patients on expectations and managing baseline comorbities. Maintaining prescribed treatment schedule while focused on quality of life remains the challenging goal for an effective treatment outcome. Biographies: Tian Zhang, MD, Ass...
|
- Details
- (Length of Discussion: 12 min) Tian Zhang and Charles Ryan highlight recent updates in the NCCN treatment guidelines for kidney cancer resulting from data leading to changes in treatment options. Incorporation of initial diagnosis, disease biology, risk category, and clinical factors assist with selecting the most appropriate therapy for these patients. Biographies: Tian Zhang, MD, Assistant Profe...
|
- Details
- Michael Harrison and Alicia Morgans discuss the ASSET trial, a pilot study looking at the drug sunitinib, and its impact on cardiopulmonary function in patients with metastatic kidney cancer. Harrison reviews in detail, the rationale for the study and why the phenomenology of fatigue using exercise physiology may be useful information for clinicians in the future. Biographies: Michael Harrison, MD...
|
- Details
- (Length of Discussion: 18 min) Tian Zhang and Alicia Morgans provide an overview of the trials that are ongoing in the advanced renal cell space. They cover a spectrum from neoadjuvant, to adjuvant, with in-depth highlights on Keynote 564. The relevance in balancing therapy choices with that of toxicities is an important part of the treatment plan for patients as well as a strong consideration in...
|
